{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:32:33Z","timestamp":1754483553285,"version":"3.37.3"},"reference-count":80,"publisher":"Informa UK Limited","issue":"14","funder":[{"DOI":"10.13039\/501100000801","name":"Bayer Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck Serono"},{"DOI":"10.13039\/100016259","name":"Mylan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roche"},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.2217\/imt-2020-0163","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T07:57:52Z","timestamp":1597046272000},"page":"1053-1066","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1080","volume":"12","author":[{"given":"Katrin","family":"Giglhuber","sequence":"first","affiliation":[{"name":"Department of Neurology, School of Medicine, Technical University Munich, Klinikum rechts der Isar, Ismaninger Str. 22, Muenchen81675, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9650-6222","authenticated-orcid":false,"given":"Achim","family":"Berthele","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, Technical University Munich, Klinikum rechts der Isar, Ismaninger Str. 22, Muenchen81675, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000694"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513507822"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00888"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3399505"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.1107"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1252"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-14"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312601"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp309"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1333-z"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09498-4"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000583"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317566"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006645"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14079"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007746"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7169-7"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315603"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.08.009"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000603"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1261-2"},{"key":"e_1_3_4_27_1","first-page":"1","article-title":"Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders","volume":"13","author":"Duchow A","year":"2020","unstructured":"Duchow A , PaulF , Bellmann-StroblJ. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Expert Opin. Biol. Ther.13, 1\u201312 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2014.10.010"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_3_4_33_1","unstructured":"Alexion Pharmaceuticals . Soliris (eculizumab) U.S. prescribing information. (2019). https:\/\/alexion.com\/documents\/soliris_uspi"},{"key":"e_1_3_4_34_1","unstructured":"European Medicines Agency (EMA) . EPAR product information Soliris\u00ae (2019). www.ema.europa.eu\/en\/ medicines\/human\/EPAR\/soliris"},{"key":"e_1_3_4_35_1","unstructured":"European Medicines Agency (EMA) . Soliris-H-C-791-II-0105: EPAR \u2013 Assessment Report \u2013 Variation (2019). www.ema.europa.eu\/documents\/variation-report\/soliris-h-c-791-ii-0105-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X14539731"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70076-0"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.156"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080043"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2011.04.014"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000289761.64862.ce"},{"issue":"1","key":"e_1_3_4_43_1","first-page":"351","article-title":"Pharmacokinetic\/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the Phase III PREVENT study (EPR2149)","volume":"27","author":"Berthele A","year":"2020","unstructured":"Berthele A , Oreja-GuevaraC , PalaceJet al. Pharmacokinetic\/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the Phase III PREVENT study (EPR2149). Eur. J. Neurol.27(Suppl. 1), 351 (2020).","journal-title":"Eur. J. Neurol."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560540"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00742-8"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2011.00328.x"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24280"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz054"},{"issue":"5","key":"e_1_3_4_50_1","first-page":"589","article-title":"Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials","volume":"85","author":"Kitley J","year":"2014","unstructured":"Kitley J , LeiteMI , ElsoneL , JacobA , PalaceJ. Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials. JNNP85(5), 589\u2013590 (2014).","journal-title":"JNNP"},{"key":"e_1_3_4_51_1","unstructured":"European Medicines Agency (EMA) . Regulatory workshop on clinical trials designs in neuromyelitis optica spectrum disorders (NMOSD). Report of EMA workshop 10 October 2014 London (2015). www.ema.europa.eu\/en\/events\/regulatory-workshop-clinical-trials-designs-neuromyelitis-optica-spectrum-disorders"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001520"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8"},{"issue":"2","key":"e_1_3_4_54_1","first-page":"737","article-title":"Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Phase III PREVENT study (P1343)","volume":"25","author":"Palace J","year":"2019","unstructured":"Palace J , PittockSJ , BertheleAet al. Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Phase III PREVENT study (P1343). Mult. Scler. J.25(S2), 737 (2019).","journal-title":"Mult. Scler. J."},{"issue":"2","key":"e_1_3_4_55_1","first-page":"294","article-title":"Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study (P612)","volume":"25","author":"Berthele A","year":"2019","unstructured":"Berthele A , PittockSJ , FujiharaKet al. Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study (P612). Mult. Scler. J.25(S2), 294 (2019).","journal-title":"Mult. Scler. J."},{"issue":"1","key":"e_1_3_4_56_1","first-page":"90","article-title":"Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the Phase III PREVENT study (O4009)","volume":"27","author":"Oreja-Guevara C","year":"2020","unstructured":"Oreja-Guevara C , PalaceJ , PittockSJet al. Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the Phase III PREVENT study (O4009). Eur. J. Neurol.27(Suppl. 1), 90 (2020).","journal-title":"Eur. J. Neurol."},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.1788"},{"issue":"2","key":"e_1_3_4_58_1","first-page":"45","article-title":"Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder (142)","volume":"25","author":"Wingerchuk DM","year":"2019","unstructured":"Wingerchuk DM , PittockSJ , BertheleAet al. Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder (142). Mult. Scler. J.25(S2), 45 (2019).","journal-title":"Mult. Scler. J."},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781450"},{"key":"e_1_3_4_61_1","unstructured":"European Medicines Agency (EMA) . Soliris SmPC. www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852919001627"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.11.015"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2014.882712"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.07.016"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502950"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-018-0517-z"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0313-y"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15790"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-018-1182-5"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102166"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1732927"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01068-2"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1691"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.07.030"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000224"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000334"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/2055217318796684"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000580"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2020-0163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:00:01Z","timestamp":1715950801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2020-0163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":80,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.2217\/imt-2020-0163"],"URL":"https:\/\/doi.org\/10.2217\/imt-2020-0163","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"type":"print","value":"1750-743X"},{"type":"electronic","value":"1750-7448"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}